about
Resistance training as a preconditioning strategy for enhancing aerobic exercise training outcomes in COPD.Heavy alcohol use in lung donors increases the risk for primary graft dysfunctionDisseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans.The prevalence and extent of gastroesophageal reflux disease correlates to the type of lung transplantationAdvances in lung transplantation: the year in review.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients.A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis.Accuracy of chest high-resolution computed tomography in diagnosing diffuse cystic lung diseases.First Spontaneous Pneumothorax: Time for Screening High-Resolution Computed Tomographic Imaging to Look for Cystic Lung Disease?Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.The 10,000-Piece Puzzle of Lymphangioleiomyomatosis.Suicidal Ideation in Lung Transplant Recipients: A Case Series.The Future of Lung TransplantationAssociations between Patient-reported Outcomes and Death or Lung transplant in IPF: Data from the IPF-PRO RegistryAdoptive T Cell Transfer to Treat LymphangioleiomyomatosisInitial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelinesPatients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseasesThe National Heart, Lung, and Blood Institute Lymphangioleiomyomatosis Registry: Making LAMonade out of LAMonsDonation after circulatory death in lung transplantation-five-year follow-up from ISHLT RegistryPreoperative Evaluation of Patients With Interstitial Lung DiseaseClinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosisAdvances in the Diagnosis and Management of Invasive Fungal DiseaseClinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis
P50
Q34036314-CBD7938E-B157-434F-8450-164AB8FE7615Q34678921-43A21594-D22D-413A-8E2B-A99DD423FEEAQ36368044-F980206F-701F-4E9F-A0A5-CE965364EA33Q37005464-C988B42C-432A-4F4D-9B32-61A08C8E09DEQ37826558-8A5D6BD3-9586-4F9C-95B1-FD3CB5189EF9Q37937344-23AE3D8B-466F-4A63-86B1-66736A64487CQ38285782-A32B33CD-BB75-4FF3-AD34-8DACFA09389FQ38676246-8B5C7CC4-DA66-44C6-A1F0-7D360F1E23FDQ40959333-C37FE0E4-21C0-463D-9194-97A5A89EAD7DQ46824754-77AADAAE-CE35-48EA-9AAB-7E3FE53C80E3Q47956605-E60D4A9B-EA9A-4A02-B567-0863F59B4BF6Q48106364-7963E5B0-3F72-4D06-8069-8AA2C4BDFE2EQ48954516-13A847D2-5BDB-4351-BAEE-5DA719D403BEQ50184923-91C2302E-CFE8-4DD7-A516-673A2C9B1CFFQ52582943-2DF57AAE-816E-41A9-82B8-8ED32557CE71Q57166872-3B0C9854-EF40-4684-8FDD-D5A3C6835C93Q89628507-AF605B26-0E17-43D0-B68D-DAAB1D7D5572Q89801224-6483CAD0-4E2E-47F3-A9BD-5D42F55288A8Q90014666-36C220CF-C5C2-43A6-8D57-B53B6EF14BFEQ90711512-7CC9C83D-BCEA-4192-8884-A14E870580E2Q91406407-446A9FD2-76BD-4F04-A329-595C97738FA4Q91500995-C18AC3C9-2B4F-4D95-A2EA-F2595866A7F6Q91555511-F3CBD305-75DC-45BF-9685-73D856A882FDQ91862467-8A946AE5-9A7C-4F70-BE94-6AFCBC459412Q92219138-7C60275B-C9F2-49CE-8F7D-E390425068F4Q92586301-DCD280A3-9E24-46D5-94FF-B3EED3D2DE88
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniel F Dilling
@ast
Daniel F Dilling
@en
Daniel F Dilling
@es
Daniel F Dilling
@nl
type
label
Daniel F Dilling
@ast
Daniel F Dilling
@en
Daniel F Dilling
@es
Daniel F Dilling
@nl
prefLabel
Daniel F Dilling
@ast
Daniel F Dilling
@en
Daniel F Dilling
@es
Daniel F Dilling
@nl
P106
P1153
36186800900
P31
P496
0000-0002-9723-510X